BRAF and cutaneous melanoma: Furthermore, whereas 42–45% of primary cutaneous melanomas carry a BRAF V600E mutation and are therefore predicted to respond to targeted BRAF-/MEK inhibition [6], UM do not carry BRAF V600E mutations [7].